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Background: A number of reports have described the presence of tuberculosis (TB) in neuromyelitis optica (NMO)
patients. However, a definite association between the two conditions has not been conclusively demonstrated.
Methods: To investigate the association between NMO and TB in a Chinese population, we performed a
retrospective review of hospital records of NMO patients, control patients and tuberculosis meningitis (TBM)
patients from January 1, 1995 to December 31, 2011.
Results: The frequency of preceding/simultaneous active pulmonary TB (PTB) was not significantly different
between NMO patients (1.1%) and control groups (2.3% in myasthenia gravis, 1.1% in polymyositis or
dermatomyositis, zero in idiopathic facial palsy and viral meningitis/meningoencephalitis). NMO cases differed
from TBM cases in terms of demographics, course (recurrent or monophasic), cerebrospinal fluid analysis and
magnetic resonance images. Two TBM patients shared partial clinical features with NMO (one of the TBM patients
had a longitudinal extensive spinal cord lesion involving the holocord, and the other had optic neuritis before
anti-tuberculosis treatment). NMO antibodies were only detected in NMO patients and not in TBM patients with
myelitis or optic neuritis.
Conclusions: We could not confirm previous suggestions of the association between PTB and NMO. Direct
infection of the central nervous system by TB may mimic NMO in some respects, but whether NMO-like symptoms
that develop during the course of TB should be considered and diagnosed as NMO is open to discussion.
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Neuromyelitis optica (NMO) is a severe demyelinating
disease of the central nervous system (CNS) that prefe-
rentially affects the optic nerve and spinal cord [1]. The
disease is idiopathic and the discovery that patients are
seropositive for aquaporin-4-specific autoantibody (AQP4-
Ab or NMO-IgG) suggested the existence of an underlying
immunopathogenic mechanism [1,2]. Although NMO usu-
ally occurs in isolation, reports over the past century have
suggested an association between NMO and tuberculosis
(TB) [3-8]. A study by Hughes and colleagues described
three patients that developed acute necrotic myelopathy
during the course of active pulmonary TB (PTB) [4]. A
report from the Western Cape of South Africa described* Correspondence: huxueqiangzssy@qq.com
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unless otherwise stated.six patients with optic neuropathy and myelopathy with
associated active PTB but no evidence of TB infection in
the CNS [3]. Another study, also carried out in South
Africa, suggested PTB-associated NMO developed in pa-
tients with active infection because 79% (11/14) of NMO
patients had a preceding or simultaneous diagnosis of PTB
[8]. Finally, Feng and colleagues described the benefits of
anti-tuberculosis treatment in steroid-refractory Chinese
NMO patients [9].
Although an association between NMO and TB has
been suggested in a number of reports from different geo-
graphical regions, a definite association between the two
conditions has not been conclusively demonstrated. Fur-
ther investigation and clarification would be helpful in the
diagnosis and treatment of patients who develop ‘NMO-
like’ symptoms (longitudinal extensive myelitis and optic
neuritis) during the course of TB. We therefore per-
formed a retrospective study to investigate whetherhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Ethical approval was given by the medical ethics commit-
tee of the third affiliated hospital of Sun Yat-sen University
with the following reference number: [2007]33. Written
informed consent was obtained from the patient for publi-
cation of the clinical data and any accompanying images.
Patients and selection criteria
To study the prevalence of PTB in NMO patients com-
pared with controls, we performed a retrospective review
of hospital records of patients with a diagnosis of NMO
that were admitted to our hospital, The Third Affiliated
Hospital of Sun Yat-Sen University, from January 1, 1995
to December 31, 2011. All NMO patients fulfilled the
2006 Wingerchuk criteria [10] (the 1999 Wingerchuk diag-
nostic criteria were used for several cases owing to a lack
of NMO-IgG data [11]). Patients with evidence of sarcoid-
osis, vasculitis, clinically manifest systemic lupus erythema-
tosus, Sjogren’s syndrome or another explanation for optic
neuritis or myelitis were excluded [12]. The control groups
consisted of patients with myasthenia gravis, polymyositis
or dermatomyositis, idiopathic facial palsy, and viral men-
ingitis/meningoencephalitis (VM). To avoid any confusion
with aseptic meningitis/meningoencephalitis, patients were
considered to have VM when either a viral etiology was
confirmed or antiviral treatment was effective. VM was
only diagnosed after ruling out bacterial, fungal, and non-
infectious causes of meningitis (malignancy, autoimmune
disorders, neurosarcoidosis) [13]. To ensure a similar back-
ground exposure to TB, control and NMO cases were
matched for sex, age at time of admission (within 10 years),
and date of admission (within a range of 5 years). If more
than one matching control was identified per case,
the one with the closest age at admission was included.
These patients were used as controls because there is no
known causal association with the risk factor under inves-
tigation (TB).
The following data were collected for all NMO and
control cases: sex, age at onset of neurological symp-
toms, and the presence or absence of a diagnosis of
active PTB [14]. Active PTB was defined either as a
diagnosis of PTB preceding the onset of NMO by fewer
than 6 months, or PTB that was not cured before admis-
sion for neurological disease. Duration from diagnosis of
PTB to onset of neurological symptoms (if previously
diagnosed with PTB), cerebrospinal fluid (CSF) data
(if available), and NMO-IgG serum status (if available)
was also collected for all cases.
To investigate whether patients with tuberculosis men-
ingitis (TBM) shared partial clinical features to NMOpatients fulfilling the 2006 Wingerchuk criteria, we also
enrolled TBM patients admitted to our hospital during
the same period using TBM criteria according to Thwaites
[15]. Detailed data on clinical presentation, CSF reports,
magnetic resonance imaging (MRI) reports, therapy, and
outcomes were collected for NMO and TBM cases. Using
MRI, spinal cord lesions extending over three or more
vertebral segments on the spinal cord were defined as lon-
gitudinal extensive spinal cord lesions (LESCLs). Linear
lesions were defined on T2-weighted imaging on MRI ac-
cording to Misu et al. [16] as: (i) consecutive linear shape
lesions on the sagittal plane and (ii) symmetric, with a
preferential involvement in the central gray matter on the
axial plane.
Serum NMO-IgG antibodies were tested according to the
manufacturer’s instructions using aquaporin 4-transfected
cells from a commercial sampling kit (EUROIMMUN AG,
Luebeck, Germany).
Statistical analysis
All statistical analyses were performed using Statistical
Program for Social Sciences (SPSS) statistical software
(version 16.0, San Francisco, CA, USA). P < 0.05 was con-
sidered statistically significant. Comparisons of the presence
of PTB between NMO patients and controls were carried
out using the Chi-squared test.
Results
We enrolled 88 patients with NMO (67 diagnosed using
the 2006 Wingerchuk diagnostic criteria and 21 using
the 1999 Wingerchuk diagnostic criteria) and 352 con-
trols into our study. The data on the presence of PTB in
NMO and control groups are shown in Table 1. One
NMO patient among the total 88 (1.1%) had a preceding
diagnosis of PTB. The frequency of active PTB in NMO
patients was not significantly different from that in
patients with myasthenia gravis, polymyositis or derm-
atomyositis, facial neuritis, and VM (P > 0.05).
The single NMO patient who had a previous history
of PTB showed no evidence (in either CSF or radiology
reports) indicative of TB infection in the CNS. She was a
26-year-old woman who experienced visual blurring
simultaneously in bilateral optic neuritis and hemiplegia
of her left limbs, 2 months prior to admission. She was
positive for NMO-IgG and the CSF protein concentra-
tion was 0.67 g/L, while glucose concentration and cell
count were normal. Brain MRI showed non-specific
white matter lesions. Spinal MRI showed a LESCL from
C1 to T5 without evidence of meningeal enhancement
or tuberculoma (Figure 1). The patient was diagnosed
with NMO. She had consolidation in her chest X-ray
3 months prior to admission. During hospitalization she
had a cough and her sputum was positive for acid-fast
bacilli. Chest radiography revealed extensive bilateral












NMO 88 (17/71) 34.1 ± 15.9 1 (1.1)
Myasthenia gravis 88 (17/71) 33.5 ± 16.9 2 (2.3) > 0.05
Polymyositis or
dermatomyositis
88 (17/71) 35.6 ± 16.3 1 (1.1) > 0.05
Idiopathic
facial palsy
88 (17/71) 39.7 ± 16.0 0 (0) > 0.05
VM 88 (17/71) 33.8 ± 14.5 0 (0) > 0.05
TB tuberculosis; PTB pulmonary tuberculosis; NMO neuromyelitis optica; VM
viral meningitis/meningoencephalitis; M male; F female; P: comparison for
active PTB presence between NMO and each control groups.
Figure 1 Spinal MRI of the NMO patient with active PTB. a: axial
T2-weighted image showing a cervical lesion predominantly involving
the central cord; b: T1-weighted contrast image revealing slight
enhancement of the lesion; c: T2-weighted image showing a
longitudinal extensive spinal cord lesion.
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lobes. Ziehl-Neelsen microscopy showed no acid-fast bacilli
in her CSF. After anti-tuberculosis treatment combined
with methylprednisolone pulse therapy, her PTB recovered,
but she had recurrent myelitis during the 17-month follow-
up period. Special MRI procedures including diffusion and
magnetic resonance spectroscopy were not performed be-
cause they were unavailable during that period. However,
taking MRI features, discussion with neurosurgeons, and
the later follow-up into consideration, intramedullary tuber-
culoma could be excluded.
Table 2 shows the demographic and clinical features of
NMO and TBM patients. Out of 92 TBM patients, 10
had myelitis (spinal meningitis, n = 2; tuberculoma, n = 1;
meningitis combined with tuberculoma, n = 2; focal or
extensive spinal lesions with hydrocephalus, meningitis or
tuberculoma in brain MRI, n = 2; clinical manifestations
indicating myelitis, n = 3). Two TBM patients had optic
neuritis, of which one developed optic neuritis before
anti-tuberculosis treatment. Compared with TBM related
myelitis (TBM-MY), NMO patients had a higher female:
male ratio (71:7 vs. 3:7), higher relapse rate of myelitis
(75% vs. 0), higher seropositive rate of NMO-IgG (82.1%
vs. 0%), and a higher frequency of normal cell count, pro-
tein, glucose and chloride concentration in the CSF. CSF
TB-antibody positivity was found in 30% (3/10) of patients
with TBM-MY, but not in NMO patients. Spinal MRI was
performed in all NMO patients and 7/10 TBM-MY
patients. There were no spinal MRI data for the three
remaining TBM-MY patients because MRI was not avail-
able at the time. However, these patients presented with
typical clinical symptoms indicating myelitis. Spinal cord
lesions in NMO patients mostly extend over multiple cord
levels involving central gray matter (linear lesions, shown
in Figure 2) or holocord (LESCLs and spinal lesions with
central/holocord involvement were found in 73.9% of
patients). Compared with NMO patients, spinal image
features of TBM-MY patients were different. Meningeal
enhancement (57.1% of patients), or tuberculoma (42.9%
of patients), which is characterized by oval lesions with
low (or iso-) T1-weighted image signal, typical ‘target sign’
T2-weighted image signal, and nodular or rim enhance-
ment in spinal cord was common (Figures 3 and 4).
Although one TBM-MY patient had LESCLs, similar to
the characteristic spinal MRI finding in NMO, the tuber-
culoma in his medulla suggested direct TB infection of
the CNS (Figure 5). Methylprednisolone pulse therapy was
administered to all NMO patients in the acute phase. Dur-
ing remission, six patients received additional immunosup-
pressants. All 92 TBM patients received anti-tuberculosis
therapy (isoniazid, rifampicin, ethambutol plus pyrazina-
mide or streptomycin for 86 patients and isoniazid, rifam-
picin, ethambutol plus second-line drugs for the remaining
six patients).
Table 2 Demographic and clinical features of NMO and TBM patients
NMO n = 88 TBM
Total n = 92 TBM-MY n = 10 TBM-ON n = 2
Sex ratio, F/M 71/7 40/52 3/7 1/1
Age, mean ± SD, years 35.3 ± 14.4 33.5 ± 18.6 34.1 ± 13.9 19, 41
Relapse of myelitis, n(%) 66/88 (75.0%) -- 0/6 (0) --
CSF
Pleocytosis, n(%) 16/88 (18.2%) 92/92 (100.0%) 10/10 (100%) 2/2 (100%)
Increased protein level, n(%) 14/88 (15.9%) 92/92 (100.0%) 10/10 (100%) 2/2 (100%)
Decreased glucose level, n(%) 1/88 (1.1%) 92/92 (100.0%) 10/10 (100%) 2/2 (100%)
TB-antibody positivity, n(%) 0/45 (0) 27/92 (29.3%) 3/10 (30%) 0/2 (0)
Mycobacterium tuberculosis, n(%) 0/45 (0) 0/92 (0) 0/10 (0) 0/2 (0)
Seropositive NMO-IgG, n(%) 55/67 (82.1%) 0/5 (0) 0/3 (0) 0/1 (0)
Spinal MRI
Linear lesions, n(%) 41/88 (46.6%) -- 0/7 (0) --
LESCLs, n(%) 65/88 (73.9%) -- 1/7 (14.3%) --
Central or holocord involvement, n(%) 65/88 (73.9%) -- 1/7 (14.3%) --
Tuberculoma, n(%) 0/88 (0) -- 3/7 (42.9%) --
Meningeal enhancement, n(%) 7/88 (8.0%) -- 4/7 (57.1%) --
Follow-up duration, median (range), months 28.5 (12–106) 14.5 (5–96) 18.0 (6–84) 24, 17
NMO neuromyelitis optica; TBM tuberculosis meningitis; TBM-MY:TBM related-melitis; TBM-ON:TBM related-optic neuritis; F female; M: male; CSF cerebrospinal fluid;
MRI magnetic resonance imaging; LESCLs longitudinal extensive spinal cord lesions.
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Several reports have suggested PTB-related NMO is
caused by an immune response to TB infection. Acute
necrotic myelopathy or NMO occurred in a few patients
with active PTB. A postmortem study found demyelin-
ation in the spinal cord without any evidence of TB in-
volvement [3,4]. The study by Hughes and colleagues
suggested tubercle bacillus, the bacterium that causes
TB, shares antigens with myelin basic protein so that
lymphocytes sensitized against mycobacterium recognizeFigure 2 Spinal cord lesion in an NMO patient. The lesions are
shown by arrows. a: T2-weighted image showing a linear-shape
lesion; b: axial T2-weighted image showing a cervical lesion
predominantly involving the central gray matter in the spinal cord.
Figure 3 Spinal MRI of a CNS-TB patient with spinal cord
involvement. a–b: meningeal and whole lesion enhancement on a
T1-weighted contrast image; c: T2-weighted image showing an
isolated lesion at the T5 level of the spinal cord.
Figure 4 Spinal MRI findings in a CNS-TB patient with spinal
cord involvement. a: tuberculoma with iso-intensity on sagittal
T1-weighted image; b: T1-weighted contrast image showing
enhancement of the whole lesion and meninges; c: tuberculoma
with iso-intensity on a sagittal T2-weighted image.
Figure 5 Spinal MRI of a CNS-TB patient with spinal cord
involvement. a: axial T2-weighted image showing central gray
matter involvement of the spinal cord. b: T1-weighted contrast
image revealing tuberculoma enhancement in the medulla but no
enhancement of the spinal cord lesion; c: T2-weighted image
showing a longitudinal extensive spinal cord lesion without a
well-demarcated boundary.
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Africa described a higher proportion of active PTB in
NMO patients compared with controls (79% vs. 14%,
P = 0.0013 < 0.05) [8]. CNS-TB was excluded in all
cases. In contrast to this previous report, we could
not confirm an association of NMO with PTB. Only
one (1.1%) of the 88 patients in the NMO group was
previously diagnosed with PTB and this was similar
to the percentage observed in the control group (P > 0.05).
Western Cape Province in South Africa had an annual TB
incidence of 517 per 100 000 in 2007 [8], while the esti-
mated national incidence for China was considerably
lower than that in South Africa (approximately 154 per
100 000 in 2006 according to World Health Organization
reports [17], and even as low as 70 per 100 000 in some
areas of China [18]). It is therefore likely that the preva-
lence of NMO in regions with a high incidence of TB is
different from the idiopathic autoimmune form seen in
areas of relatively low TB incidence.
Another possible explanation for TB-related NMO
relates to a nonspecific adjuvant effect of TB that ampli-
fies the immune response. It is relatively easy to induce
an autoimmune disease in genetically susceptible ani-
mals via immunization with complete Freund’s adjuvant
(containing inactivated M. tuberculosis) and an autoanti-
gen [19-21]. Although we do not know to what extent
the adjuvant effect of M. tuberculosis contributes to the
pathogenesis of the experimental autoimmune encephal-
itis (EAE) model, a myelin-specific antigen in incomplete
Freund’s adjuvant lacking M. tuberculosis can also in-
duce EAE in marmosets [22], suggesting that, at least insome species, this agent is not necessary for induction
of EAE.
It has also been proposed that some NMO cases are
caused by a direct CNS infection with tuberculosis. In a
small controlled study carried out by Feng and colleagues
from China, positivity for M. tuberculosis DNA in the CSF
of 2 out of 12 steroid-refractory NMO patients (confirmed
using nested polymerase chain reaction and the long-term
clinical efficacy of anti-tuberculosis treatment in these
patients) suggested pathogenesis involves direct CNS in-
fection [9]. However, it is possible that Feng et al.’s study
may have been subjected to selection bias because the
authors used the original criteria for NMO diagnosis
(Wingerchuck 1999), which did not require NMO-IgG
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malities (CSF protein levels were increased in 53.9% of
patients and 50% had elevated CSF leukocyte counts) [9].
The present study used the newer, revised criteria that are
more specific for NMO diagnosis than the original criteria
[10]. Contrary to the findings in Feng et al.’s study, ele-
vated protein level (15.9% of patients) and pleocytosis
(18.2% of patients) in CSF were not common in our NMO
patients (Table 2). Although these relatively low frequen-
cies contrast with some reports from Western countries
(which found abnormal CSF cell counts in the majority of
patients in the acute phase [11,23]), our data are consist-
ent with some previous studies carried out in Asia (27.3%
of NMO patients had CSF pleocytosis in southern China
[24], 25% in Japan [25], and 0 in Iran [26]).
Although our data show that TBM patients may
develop myelitis or optic neuritis, many of these TBM
patients can be differentiated from NMO patients on the
basis of demographics, course (recurrent or monopha-
sic), CSF, and neuroimaging features. However, it is
worthwhile to note that two TBM patients shared partial
clinical features with NMO; one of the TBM patients
had LESCLs involving holocord, similar to the charac-
teristic spinal MRI finding in NMO, and the other had
optic neuritis before anti-tuberculosis treatment. This
finding supports the notion that direct TB infection of
the CNS may incidentally mimic NMO in some aspects.
The presence of NMO-IgG has rarely been tested in
‘TB-related NMO’ cases in older studies because NMO-
IgG was not discovered until 2004 [2]. Only one report
has described two patients who developed NMO-like
symptoms during the course of TB, but both patients
showed seronegativity for NMO-IgG [7]. Consistent with
this previous report, the two patients who shared partial
clinical features with NMO in our study were also nega-
tive for NMO-IgG. We presume that these NMO-like
symptoms with NMO-IgG negativity may differ from
NMO with NMO-IgG positivity. In fact, reports have
shown that NMO-IgG negative NMO differs clinically
and epidemiologically from NMO-IgG positive disease
and may even have a distinct pathogenesis [27]. Despite
the high specificity of NMO-IgG for diagnosis of NMO
[1,2,10], NMO-IgG negativity cannot rule out its diagno-
sis absolutely. This is because NMO-IgG levels and even
serostatus can vary during follow-up [28]. Thus, diseases
that mimic NMO, including CNS infections with a focus
on the spinal cord and optic nerves, still have the poten-
tial to be diagnosed as NMO with NMO-IgG negativity.
Recently, Miller and co-workers suggested that patients
showing evidence of another explanation for ‘NMO-like’
symptoms should be excluded from NMO diagnosis
[12]. Therefore, it is still debatable whether NMO-like
symptoms that develop during the course of TB should
be considered and diagnosed as NMO.Conclusions
The nature of NMO and its association with TB in the
Chinese population may differ from populations from
other regions. We could not confirm previous sugges-
tions of an association between PTB and NMO. Direct
TB infection of CNS may incidentally mimic NMO in
some respects, but whether NMO-like symptoms that
develop during the course of TB are diagnosed and
treated as NMO is open to discussion. Although our
findings argue against a causal association of NMO and
TB, this study is limited by its retrospective design. We
only focused on the relationship between NMO and active
PTB and TBM because of limited datasets. A broader
association of TB (for instance, distant or treated TB) and
NMO should also be explored. Moreover, TB (the risk
factor) does not occur at a sufficiently high frequency in
either NMO patients or controls in our study to draw a
definitive conclusion; therefore, a possible association be-
tween NMO and TB may be missed because of the small
sample size. A larger prospective investigation with a
long-term follow-up will be helpful in answering this
question.
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